Plasma levels of lipoproteins are major risk factors for coronary heart disease (CHD). Our laboratory has used human genetics to elucidate the physiology and pathophysiology of circulating lipoproteins, and identify new targets for therapeutic intervention. Here we focus on the angiopoietin-like proteins 3 and 8 (ANGPTL3 and ANGPTL8), which exert powerful effects on lipoprotein metabolism. Humans lacking ANGPTL3 have striking panhypolipidemia, with marked reductions in plasma levels of LDL-cholesterol and triglycerides (TG). In the last funding period we showed that ANGPTL8 (A8) is a paralog of ANGPTL3 (A3)) that acts together with its progenitor to direct trafficking of circulating TG to peripheral tissues. Deficiency of ANGPTL8 reduces plasma levels of TG in both humans and mice. More recently, our group demonstrated that A3 and A8 both play a critical role in energy metabolism. Mice lacking the two genes are hypermetabolic, with increased body temperatures, increased VO2 and impaired fat accumulation. In contrast to the extensive literature on the effect of genetic differences in A3 and A8 on circulating lipoproteins, virtually nothing is known about the roles of these two proteins in energy metabolism. In this proposal, we will address 3 questions: 1) What are the roles of A3 and A8 in lipid and energy metabolism? 2) What is the potential therapeutic utility of inactivating A3 and/or A8? 3) How does variation in plasma A3 or A8 levels impact on other metabolic pathways humans? In Aim 1, genetically-modified mice will be used to investigate the actions of A3 and A8 on TG trafficking and energy metabolism. Unlike A3, A8 is expressed in adipose tissue as well as liver; therefore, we will use tissue-specific A8 KO mice to determine the function of A8 in the two tissues. We will then investigate the metabolic and molecular basis for the remarkable and unexpected increases in body temperature and basal metabolic rate observed in mice lacking both A3 and A8.
In Aim 2 we will use monoclonal antibodies (mAbs) to assess the therapeutic potential of singly and jointly inactivating circulating A3 and A8.
In Aim 3 we will use newly developed anti-A8 antibodies (Ab) to establish a sensitive and specific ELISA to quantify A8 in plasma. For these studies we will take advantage of a well-characterized population-based study that we established in Dallas, the Dallas Heart Study, to determine how plasma levels of A8 are related to metabolic and cardiovascular disease in humans. The reagents and expertise required for the studies outlined in this grant are already established in our laboratory. Successful completion of these studies will elucidate an important metabolic pathway and could provide the impetus for development of a new generation of lipid-lowering drugs that reduce plasma lipid levels and promote energy utilization. C/PPG 2015 ? RP4 ? 30-line Summary

Public Health Relevance

The angiopoietin-like proteins 3 and 8 (A3 and A8) have powerful effects on plasma lipids and energy metabolism and are attractive therapeutic targets for metabolic diseases. In this application, we will address fundamental questions regarding the mechanisms of action of A3 and A8, the metabolic effects of A3 and A8 inhibitors, the genetic determinants of A3 and A8 levels, and the relationship between A3 and A8 and other metabolic traits and clinical end-points. C/PPG 2015 ? RP4 ? Project Narrative

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL020948-41
Application #
9278891
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Liu, Lijuan
Project Start
Project End
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Mitsche, Matthew A; Hobbs, Helen H; Cohen, Jonathan C (2018) Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem 293:6958-6968
Banfi, Serena; Gusarova, Viktoria; Gromada, Jesper et al. (2018) Increased thermogenesis by a noncanonical pathway in ANGPTL3/8-deficient mice. Proc Natl Acad Sci U S A 115:E1249-E1258
Fine, Michael; Schmiege, Philip; Li, Xiaochun (2018) Structural basis for PtdInsP2-mediated human TRPML1 regulation. Nat Commun 9:4192
Linden, Albert G; Li, Shili; Choi, Hwa Y et al. (2018) Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice. J Lipid Res 59:475-487
Johnson, Brittany M; DeBose-Boyd, Russell A (2018) Underlying mechanisms for sterol-induced ubiquitination and ER-associated degradation of HMG CoA reductase. Semin Cell Dev Biol 81:121-128
Qi, Xiaofeng; Schmiege, Philip; Coutavas, Elias et al. (2018) Two Patched molecules engage distinct sites on Hedgehog yielding a signaling-competent complex. Science 362:
Engelking, Luke J; Cantoria, Mary Jo; Xu, Yanchao et al. (2018) Developmental and extrahepatic physiological functions of SREBP pathway genes in mice. Semin Cell Dev Biol 81:98-109
Hobbs, Helen H (2018) Science, serendipity, and the single degree. J Clin Invest 128:4218-4223
Muse, Evan D; Yu, Shan; Edillor, Chantle R et al. (2018) Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages. Proc Natl Acad Sci U S A 115:E4680-E4689
DeBose-Boyd, Russell A; Ye, Jin (2018) SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond. Trends Biochem Sci 43:358-368

Showing the most recent 10 out of 766 publications